{"gene":"ALOX5","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1999,"finding":"The ALOX5 core promoter contains a variable number of Sp1/Egr1-binding tandem repeats; variants with other than five repeats show diminished promoter-reporter activity in tissue culture, leading to reduced ALOX5 transcription and decreased leukotriene production, which predicts differential clinical response to ALOX5-pathway modifiers in asthma.","method":"Promoter-reporter (luciferase) assay in tissue culture; pharmacogenetic clinical association study","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1–2 — functional promoter assay plus clinical pharmacogenetic validation; widely replicated across multiple subsequent studies","pmids":["10369259"],"is_preprint":false},{"year":2006,"finding":"Eosinophils bearing the ALOX5 promoter non5/non5 genotype express less ALOX5 mRNA and produce less LTC4 than those with the 5/5 genotype, directly linking the tandem-repeat polymorphism to reduced enzyme expression and leukotriene output in primary human cells.","method":"In vitro eosinophil culture; RT-PCR for ALOX5 mRNA; LTC4 ELISA; genotyping","journal":"Allergy","confidence":"Medium","confidence_rationale":"Tier 2 — functional measurement in primary cells from genotyped donors; single lab","pmids":["16364163"],"is_preprint":false},{"year":2009,"finding":"Alox5 is required for BCR-ABL-induced chronic myeloid leukemia (CML) in mice; loss of Alox5 impairs differentiation, cell division, and survival of long-term leukemia stem cells (LT-LSCs) without significantly affecting normal hematopoietic stem cells, preventing CML development.","method":"Alox5 knockout mouse model; BCR-ABL bone marrow transplantation CML model; colony-forming and replating assays; flow cytometry for LSC populations; pharmacological inhibition with zileuton","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function in vivo with specific cellular phenotype; replicated with pharmacological inhibitor; highly cited foundational paper","pmids":["19503090"],"is_preprint":false},{"year":2009,"finding":"The 5-lipoxygenase product 5S-HETE is oxygenated by COX-2 to yield a bicyclic di-endoperoxide; heme (hematin or ferrous iron) catalyzes cleavage of both peroxide O–O bonds to generate 4S-HNE, 8-oxo-5S-hydroxy-6E-octenoic acid, and malondialdehyde, identifying a convergent ALOX5/COX-2 pathway that produces canonical lipid peroxidation products.","method":"In vitro enzymatic assay with purified hematin/ferrous chloride; HPLC product analysis; chiral-phase HPLC for stereochemical assignment","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with product characterization and stereochemical validation","pmids":["19553698"],"is_preprint":false},{"year":2011,"finding":"ALOX5 inhibition with zileuton or knockdown of Alox5 expression reduces ALOX5 activity and impairs insulin secretion in pancreatic islets; Alox5-/- mice show increased fat mass, impaired glucose-stimulated insulin secretion, and decreased insulin/PDX1 gene expression; siRNA knockdown of ALOX5 in human islets phenocopies this, demonstrating a direct role for 5-LO in pancreatic beta-cell function.","method":"Alox5 knockout mice; in vivo glucose tolerance tests; isolated islet insulin secretion assays; siRNA knockdown in human islets; RT-PCR for insulin and PDX1","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 1–2 — genetic KO and siRNA in human islets with orthogonal functional readouts; published as independent replication of mouse and human findings","pmids":["18421434"],"is_preprint":false},{"year":2012,"finding":"Reduction of the substrate-binding pocket volume of mouse Alox5 by multiple mutations (Phe359Trp + Ala424Ile + Asn425Met) converts it from a 5-lipoxygenating enzyme to a dominant 15S-lipoxygenating enzyme; the same triad mutations in human ALOX5 yield the same result, establishing that pocket geometry determines reaction specificity.","method":"Site-directed mutagenesis; recombinant enzyme expression; HPLC product analysis; structural modeling","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with mutagenesis and product characterization; confirmed in both mouse and human enzyme","pmids":["23246375"],"is_preprint":false},{"year":2013,"finding":"Cannabinoid receptor 2 (Cnr2) activation suppresses leukocyte inflammatory migration by downregulating Alox5 expression through inhibition of the JNK/c-Jun signaling axis; alox5 is a direct transcriptional target of c-Jun; genetic inactivation of Alox5 blocks leukocyte migration in zebrafish, establishing a Cnr2–JNK–c-Jun–Alox5 pathway.","method":"Chemical genetic screen in zebrafish; zinc finger nuclease-mediated Cnr2 and Alox5 mutagenesis; leukocyte migration assays; JNK/c-Jun inhibitor studies; human myeloid cell validation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in zebrafish with mechanistic follow-up in human cells; multiple orthogonal methods","pmids":["23539630"],"is_preprint":false},{"year":2013,"finding":"RUNX1-ETO9a upregulates Alox5 via the C2H2 zinc finger transcription factor KLF6; KLF6 is required for Alox5 induction by RUNX1-ETO9a, and KLF6 is specifically upregulated by RUNX1-ETO in human leukemia cells; loss of Alox5 reduces activity of RUNX1-ETO9a, MLL-AF9, and PML-RARα in vitro.","method":"ChIP assays; loss-of-function (shRNA/KO) in leukemia cell models; bone marrow transplantation assay; colony-forming assay","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis and ChIP in leukemia models; single lab but multiple approaches","pmids":["24130502"],"is_preprint":false},{"year":2014,"finding":"Genetic deletion of ALOX5 in triple-transgenic Alzheimer's disease mice (3xTg/5LO-/-) prevents stress-induced tau hyperphosphorylation, increased GSK3β activity, long-term potentiation impairment, and fear-conditioned memory deficits caused by restraint/isolation stress, establishing that ALOX5 mediates stress-dependent propagation of Alzheimer's-like tauopathy.","method":"Genetic knockout (3xTg/5LO-/-); restraint/isolation stress paradigm; LTP electrophysiology; fear-conditioning behavior; Western blot for phospho-tau and GSK3β","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO with defined electrophysiological and behavioral phenotype; single lab","pmids":["25122659"],"is_preprint":false},{"year":2015,"finding":"Zebrafish ALOX2 is a functional ortholog of human ALOX5: it oxygenates arachidonic acid at the 5S position and also exhibits leukotriene synthase activity; triad determinant mutagenesis (Phe359Trp, Ala424Ile, Asn425Met) shifts reaction specificity from 5S- to dominant 15S-lipoxygenation, confirming that the same catalytic determinants govern positional specificity in both vertebrate orthologs.","method":"Recombinant expression in pro- and eukaryotic systems; HPLC product analysis; site-directed mutagenesis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis confirming catalytic mechanism","pmids":["26456699"],"is_preprint":false},{"year":2016,"finding":"JAK2V617F strongly upregulates Alox5 expression in hematopoietic cells; genetic deletion or pharmacological inhibition of Alox5 attenuates polycythemia vera (PV) development in mice by inducing cell-cycle arrest and apoptosis in PV cells and suppressing PV-initiating cells; mechanistically, Alox5 inhibition reduces AKT activation and decreases β-catenin expression in JAK2V617F-expressing cells.","method":"JAK2V617F PV mouse model; Alox5 knockout; zileuton pharmacological inhibition; colony formation from human JAK2V617F CD34+ cells; Western blot for AKT and β-catenin","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus pharmacological inhibition with defined molecular mechanism; validated in human CD34+ cells","pmids":["27784744"],"is_preprint":false},{"year":2017,"finding":"ALOX5 is transcriptionally repressed in MLL-rearranged AML via Polycomb repressive complex 2 (PRC2); restoration of Alox5 expression sensitizes MLL-rearranged leukemic cells to doxorubicin and cytarabine, with Stat and K-Ras signaling pathways negatively correlated with Alox5 overexpression.","method":"Affymetrix microarray; ChIP assay for PRC2; colony-forming and bone marrow transplantation assays; drug sensitivity assays in vitro and in vivo","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirming PRC2-mediated repression plus functional rescue experiments in vivo; single lab","pmids":["28500307"],"is_preprint":false},{"year":2017,"finding":"Profilin 1 (PFN1) secreted by invasive extravillous trophoblasts induces decidualization of human endometrial stromal cells and downregulates ALOX5 expression in these stromal cells and in THP-1 macrophages, identifying a PFN1–ALOX5 signaling axis in decidualization during early pregnancy.","method":"Primary human endometrial stromal cell culture; recombinant PFN1 treatment; Western blot and qPCR for ALOX5; immunolocalization of ALOX5 in first-trimester decidua","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 — functional cell-based assay with protein localization; single lab, moderate follow-up","pmids":["28821715"],"is_preprint":false},{"year":2019,"finding":"Mutagenesis of the triad determinants (Phe359Trp/Ala424Ile/Asn425Met/Ala603Ile) in human ALOX5 abolishes its 5S-lipoxygenating and leukotriene synthase activity, instead producing 15(S)- and 8(S)-HpETE; structural docking, molecular dynamics, and QM/MM calculations confirm that these mutations alter substrate orientation within the active site cavity, linking pocket geometry to reaction specificity.","method":"Recombinant expression in Sf9 insect cells; HPLC product characterization; kinetic studies with stereospecifically deuterium-labeled substrates; in silico docking, MD simulation, QM/MM","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis, product characterization, stereochemical probes, and computational validation","pmids":["31664810"],"is_preprint":false},{"year":2020,"finding":"Mass spectrometric DNA pulldown of the ALOX5 proximal promoter identified 66 specific binding proteins; key transcriptional regulators include known factors Sp1, Sp3, and Sp2, Krüppel-like factors KLF13 and KLF16, and zinc finger proteins MAZ, PRDM10, VEZF1, ZBTB7A, ZNF281, ZNF579; helicases BLM and DHX36, and hnRNPD/hnRNPK (G-quadruplex interactors) were also identified; spectroscopic and antibody methods confirmed that the GC-rich ALOX5 promoter forms DNA G-quadruplex structures that may regulate transcription.","method":"DNA pulldown coupled to label-free quantitative mass spectrometry; circular dichroism spectroscopy; antibody-based G-quadruplex detection","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 — systematic proteomics pulldown with orthogonal structural confirmation; single lab","pmids":["32096311"],"is_preprint":false},{"year":2020,"finding":"LPS activates the ALOX5 promoter and increases 5-LO mRNA and protein expression in human monocytic cells (MM1, THP-1); LPS and TGF-β synergistically increase 5-LO product biosynthesis; LPS-driven ALOX5 promoter activation does not affect LTA4 metabolism, indicating LPS specifically upregulates early steps of leukotriene biosynthesis.","method":"ALOX5 promoter-luciferase reporter assay; RT-PCR and Western blot for 5-LO; HPLC-based 5-LO product measurement","journal":"Prostaglandins, leukotrienes, and essential fatty acids","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay plus functional leukotriene biosynthesis measurement; single lab","pmids":["32120263"],"is_preprint":false},{"year":2021,"finding":"PKC-β overexpression drives BCR-ABL-independent TKI resistance in CML by upregulating Alox5 through ERK1/2 signaling; Alox5 in turn inactivates PTEN, sustaining TKI insensitivity; inhibition of PKC-β restores imatinib sensitivity in CD34+ CML cells and prolongs survival in a CML-PDX mouse model.","method":"shRNA knockdown; gene expression profiling (84-gene leukemia array); ERK1/2 pathway inhibitors; PTEN activity assays; in vivo PDX model with PKC-β inhibitor LY333531","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis established in cell lines and PDX with mechanistic follow-up; single lab","pmids":["33561320"],"is_preprint":false},{"year":2021,"finding":"ALOX5 produces 5-HETE from arachidonic acid in gastric cancer cells; ALOX5 overexpression or exogenous 5-HETE activates MEK/ERK signaling to promote gastric cancer cell growth and reduce chemotherapy sensitivity, while ALOX5 inhibition suppresses ERK activation and sensitizes cells to chemotherapy.","method":"ALOX5 overexpression and pharmacological inhibition; phospho-ERK Western blot; cell growth and survival assays; 5-HETE ELISA","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function and loss-of-function with defined pathway readout; single lab","pmids":["34121352"],"is_preprint":false},{"year":2022,"finding":"Erk1-dependent phosphorylation of Alox5 targets it to the nuclear membrane where it mediates lipid peroxidation; resulting nuclear translocation of cytolytic molecules causes DNA damage and cell death independently of caspase-9; double knockout of caspase-9 and Alox5 in mice causes significant T cell expansion, demonstrating that these pathways function in parallel to regulate T cell death in vivo.","method":"Genome-wide siRNA library screen; caspase-9/Alox5 double-knockout mice; ROS and lipid peroxidation assays; subcellular fractionation/imaging; T cell proliferation/apoptosis assays","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1–2 — unbiased genome-wide screen followed by genetic double-KO validation in vivo with mechanistic imaging/biochemical readouts","pmids":["36231015"],"is_preprint":false},{"year":2022,"finding":"LysOX promotes ferroptosis-associated lipid peroxidation in neurons via ERK-dependent activation of Alox5 (5-lipoxygenase) signaling; AAV-mediated LysOX overexpression enhances ferroptosis sensitivity and seizure-induced hippocampal damage, while pharmacological LysOX inhibition blocks seizure-induced Alox5-mediated ferroptosis.","method":"AAV-based LysOX overexpression in vivo; LysOX pharmacological inhibition (BAPN); ERK inhibitor studies; lipid peroxidation assays; seizure mouse model","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo gain- and loss-of-function with mechanistic pathway (ERK-Alox5) established; single lab","pmids":["36176900"],"is_preprint":false},{"year":2023,"finding":"HTTQ94 (polyglutamine-expanded N-terminal huntingtin fragment) activates ALOX5-mediated ferroptosis by stabilizing FLAP (5-LO activating protein), an essential cofactor of ALOX5 lipoxygenase activity; ALOX5 is required for HTTQ94-induced ferroptosis in response to ROS stress and glutamate, but is dispensable for common ferroptosis inducers (e.g., erastin); Alox5 genetic inactivation ameliorates HD pathology and extends lifespan in HD mice.","method":"RNAi-mediated genome screen; ALOX5 and FLAP co-immunoprecipitation/stabilization assays; neuronal cell ferroptosis assays; Alox5 knockout in HD mice; behavioral and pathological phenotyping","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 — unbiased RNAi screen, biochemical FLAP stabilization mechanism, and in vivo genetic rescue; multiple orthogonal methods","pmids":["36921996"],"is_preprint":false},{"year":2023,"finding":"ALOX5 promotes macrophage M2 polarization via the JAK/STAT pathway; lentiviral ALOX5 overexpression in macrophages induces M2-like phenotype and promotes chemotaxis toward pancreatic cancer cells; zileuton inhibits these effects by blocking ALOX5, reducing tumor invasion and liver metastasis in an orthotopic pancreatic cancer mouse model.","method":"Lentiviral ALOX5 overexpression; JAK/STAT pathway inhibitors; in vitro macrophage polarization assays; orthotopic nude mouse model; survival analysis","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function in vitro and in vivo with defined JAK/STAT pathway mechanism; single lab","pmids":["37348233"],"is_preprint":false},{"year":2023,"finding":"ALOX5 deficiency in bladder cancer cells permits ferroptosis escape; EGR1 transcriptionally regulates ALOX5 expression; CRISPR/Cas9 and RNAi loss-of-function confirmed that ALOX5 is required for ferroptosis sensitivity, with ALOX5-deficient high-pathological-stage bladder cancer cells showing ferroptosis resistance.","method":"CRISPR/Cas9 knockout; RNAi knockdown; RNA-seq; ferroptosis assays (lipid peroxidation, cell death); ChIP/reporter assays for EGR1-ALOX5 transcriptional regulation","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR KO plus transcriptional mechanism; single lab","pmids":["38062004"],"is_preprint":false},{"year":2023,"finding":"In intrahepatic cholangiocarcinoma, ALOX5-derived LTB4 binds BLT1/BLT2 receptors on tumor-associated macrophages (TAMs) and activates the PI3K pathway to promote M2 macrophage migration toward tumor cells; co-culture and bulk-sequencing confirmed PI3K as the key downstream pathway; combined ALOX5 inhibitor (zileuton) and CSF1R inhibitor reduced tumor volume and M2 macrophage infiltration in a xenograft model.","method":"In vitro macrophage co-culture model; LTB4 ELISA; BLT1/BLT2 receptor blocking; PI3K pathway inhibitors; bulk RNA-seq after co-culture; xenograft nude mouse model","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic in vitro and in vivo data with receptor and pathway identification; single lab","pmids":["38124204"],"is_preprint":false},{"year":2023,"finding":"ALOX5 promotes autophagy-dependent ferroptosis in melanoma by activating the AMPK/mTOR pathway and inhibiting GPX4 expression; inhibition of autophagy reduces ALOX5-enhanced ferroptosis, indicating that ALOX5 and autophagy are synergistic; recombinant human ALOX5 protein exerts antitumor ferroptotic effects in a xenograft model.","method":"ALOX5 overexpression in melanoma cell lines and xenograft; AMPK/mTOR pathway analysis by Western blot; autophagy inhibitors; GPX4 expression; MDA/GSH/iron assays","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function with defined AMPK/mTOR mechanism; in vivo validation; single lab","pmids":["37080437"],"is_preprint":false},{"year":2024,"finding":"ALOX5 activity in RA CD4+ T cells increases LTB4 production; LTB4 stimulates Ca2+ influx through ORAI3 channels, leading to NLRP3 inflammasome activation and pyroptosis; ALOX5 knockdown or pharmacological inhibition suppresses CD4+ T cell pyroptosis and improves symptoms in two rodent RA models.","method":"ALOX5 mRNA/protein quantification in patient T cells; ALOX5 knockdown; LTB4 ELISA; Ca2+ flux assays; ORAI3 blocking; NLRP3 inflammasome activation assays; rodent RA models","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic pathway (ALOX5→LTB4→ORAI3→NLRP3→pyroptosis) established with multiple orthogonal biochemical methods and validated in two in vivo models with patient-derived cells","pmids":["38412254"],"is_preprint":false},{"year":2024,"finding":"In lung cancer-educated neutrophils, PARP-1 interacts with and PARylates (post-translationally modifies) ALOX5, stabilizing ALOX5 protein; this stabilization increases MMP-9 expression and promotes lung cancer cell invasion and tumor growth in vivo; PARP-1 knockdown or inhibition (AG14361) decreases ALOX5 expression and MMP-9 production, eliminating neutrophil-mediated cancer promotion.","method":"Co-immunoprecipitation; immunoprecipitation coupled to mass spectrometry (IP/MS); PARylation assay; gene knockdown; gelatin zymography for MMP-9; murine tumor model","journal":"Cancer biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP/MS identification of PARP-1–ALOX5 interaction with PARylation mechanism and in vivo functional validation; single lab","pmids":["38172525"],"is_preprint":false},{"year":2024,"finding":"ALOX5-derived 5-HETE from glioma cells promotes M2 polarization, PD-L1 expression, and migration of glioma-associated microglia/macrophages (GAMs) by facilitating nuclear translocation of NRF2; an anti-ALOX5 nanobody suppresses 5-HETE efflux, attenuates M2 GAM polarization, and reduces glioma progression; combination with anti-PD-1 shows superior anti-tumor efficacy.","method":"UHPLC-MS/MS oxylipin profiling; in vivo orthotopic glioma model with bioluminescence imaging; flow cytometry; immunofluorescence; NRF2 nuclear translocation assay; ALOX5-targeted nanobody; anti-PD-1 combination therapy","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway (ALOX5→5-HETE→NRF2 nuclear translocation→M2/PD-L1) established with oxylipin profiling and in vivo rescue; single lab","pmids":["39142719"],"is_preprint":false},{"year":2007,"finding":"5-LOX is expressed in both resting peripheral blood T lymphocytes and T lymphoblastoid cell lines at the mRNA and protein level; the enzyme localizes primarily to the cytoplasm with some nuclear localization and translocates to the nuclear periphery following mitogenic stimulation; Jurkat cells, but not resting primary T cells, produce LTC4 and LTB4 upon CD3/CD28 cross-linking, and this synthesis is abolished by MK-886 and AA-861 (5-LO inhibitors), demonstrating stimulus-dependent translocation-linked enzymatic activation.","method":"RT-PCR; in situ RT-PCR; Western blot; immunofluorescence; FACS; LTC4/LTB4 synthesis assay with pharmacological inhibitors","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct subcellular localization linked to functional leukotriene production; multiple orthogonal methods; single lab","pmids":["17484769"],"is_preprint":false},{"year":2000,"finding":"5-LOX mRNA and protein are increased in hippocampus and cerebellum of aging rats, and the membrane/cytosol ratio of 5-LOX protein is larger in older versus younger brains, indicating that aging drives both increased ALOX5 expression and translocation/activation of the enzyme to membranes.","method":"Quantitative RT-PCR with internal standards; quantitative Western blotting; subcellular fractionation","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 — direct subcellular fractionation demonstrating translocation linked to aging; single lab","pmids":["11016533"],"is_preprint":false}],"current_model":"ALOX5 encodes arachidonate 5-lipoxygenase, a key enzyme that converts arachidonic acid to 5(S)-HpETE and subsequently to leukotrienes (including LTB4) and 5-HETE; its reaction specificity is determined by the geometry of triad determinants (Phe359/Ala424/Asn425/Ala603) lining the substrate-binding pocket, and its activity is regulated by nuclear/membrane translocation, by FLAP (stabilized in Huntington's disease by mutant huntingtin), by post-translational PARylation via PARP-1, and transcriptionally through Sp1/Egr1 tandem-repeat promoter elements, KLF6, PRC2, and LPS-driven signaling; downstream, ALOX5 drives leukocyte migration via JNK/c-Jun, promotes CD4+ T cell pyroptosis through LTB4–ORAI3–NLRP3, mediates ferroptosis through ACSL4-independent lipid peroxidation at the nuclear membrane via Erk1-dependent phosphorylation, supports leukemia stem cell survival in CML/PV through AKT and β-catenin, and regulates pancreatic beta-cell insulin secretion, with loss-of-function models in mice and human cells confirming these mechanistic roles."},"narrative":{"teleology":[{"year":1999,"claim":"The question of how ALOX5 transcription is regulated was addressed by identifying a variable tandem-repeat element of Sp1/Egr1 sites in the core promoter, establishing that copy-number variation at this locus controls enzyme expression and leukotriene output.","evidence":"Promoter-reporter assays in tissue culture combined with pharmacogenetic clinical association in asthma patients","pmids":["10369259"],"confidence":"High","gaps":["Mechanism by which non-5 repeat alleles reduce transcription not fully resolved","Identity of chromatin remodeling factors at the tandem-repeat locus unknown"]},{"year":2000,"claim":"Whether ALOX5 expression and subcellular distribution change with aging was answered by showing increased mRNA/protein and enhanced membrane translocation in aged rat brain, establishing that aging itself upregulates and activates ALOX5.","evidence":"Quantitative RT-PCR, Western blotting, and subcellular fractionation in young versus aged rat hippocampus and cerebellum","pmids":["11016533"],"confidence":"Medium","gaps":["Causal relationship between membrane translocation and age-related neuroinflammation not tested","Human aging tissue not examined"]},{"year":2006,"claim":"The functional impact of promoter tandem-repeat variation in primary human cells was confirmed by showing that eosinophils homozygous for non-5 repeat alleles produce less ALOX5 mRNA and LTC4, validating the promoter polymorphism as a determinant of leukotriene biosynthetic capacity.","evidence":"RT-PCR and LTC4 ELISA in genotyped primary human eosinophils","pmids":["16364163"],"confidence":"Medium","gaps":["Sample size limited","Whether other cell types show the same quantitative relationship is untested"]},{"year":2007,"claim":"The question of how ALOX5 is activated in lymphocytes was addressed by demonstrating that the enzyme resides in the cytoplasm of resting T cells and translocates to the nuclear periphery upon mitogenic stimulation, coupling subcellular redistribution to leukotriene synthesis.","evidence":"Immunofluorescence, subcellular fractionation, and leukotriene synthesis assays with pharmacological inhibitors in primary T cells and Jurkat cells","pmids":["17484769"],"confidence":"Medium","gaps":["Stimulus-specific translocation signals not identified","Whether translocation requires FLAP in T cells not tested"]},{"year":2009,"claim":"A convergent lipid peroxidation pathway was revealed when 5S-HETE (the ALOX5 product) was shown to be further oxygenated by COX-2 to yield a di-endoperoxide whose heme-catalyzed cleavage generates 4S-HNE and malondialdehyde, connecting ALOX5 to canonical oxidative damage markers.","evidence":"In vitro reconstitution with purified enzymes and heme; HPLC with chiral-phase stereochemical assignment","pmids":["19553698"],"confidence":"High","gaps":["Cellular relevance of this convergent pathway not demonstrated in intact cells","Relative contribution versus direct lipid peroxidation unknown"]},{"year":2009,"claim":"The long-standing question of whether ALOX5 is dispensable for normal hematopoiesis but essential for leukemia was answered by showing that Alox5 knockout prevents CML development by selectively eliminating leukemia stem cells while sparing normal HSCs.","evidence":"Alox5 knockout mice; BCR-ABL bone marrow transplantation CML model; colony-forming assays; zileuton validation","pmids":["19503090"],"confidence":"High","gaps":["Direct molecular target of ALOX5 products in LSCs not identified at this stage","Whether ALOX5 inhibition eradicates established CML not tested"]},{"year":2011,"claim":"ALOX5 was established as a regulator of pancreatic β-cell function: Alox5−/− mice show impaired glucose-stimulated insulin secretion and reduced insulin/PDX1 expression, phenocopied by siRNA in human islets, extending ALOX5 biology beyond immunity.","evidence":"Alox5 knockout mice with glucose tolerance tests; isolated islet insulin secretion assays; siRNA in human islets","pmids":["18421434"],"confidence":"High","gaps":["Which specific ALOX5 product mediates β-cell signaling is unknown","Downstream signaling pathway linking 5-LO to PDX1 expression not defined"]},{"year":2012,"claim":"The structural basis of ALOX5 positional specificity was established by showing that mutagenesis of three triad determinants (Phe359Trp/Ala424Ile/Asn425Met) converts the enzyme from 5S- to dominant 15S-lipoxygenation in both mouse and human orthologs, proving that active-site pocket geometry dictates substrate oxygenation position.","evidence":"Site-directed mutagenesis of recombinant mouse and human ALOX5; HPLC product analysis; structural modeling","pmids":["23246375"],"confidence":"High","gaps":["Crystal structure of mutant enzyme not determined","Whether these residues also control LTA4 synthase activity not tested"]},{"year":2013,"claim":"ALOX5 was placed in a transcriptional signaling cascade for leukocyte migration: Cnr2 suppresses migration by inhibiting JNK/c-Jun-dependent ALOX5 transcription, while in AML, KLF6 is required for oncogene-driven ALOX5 upregulation, establishing ALOX5 as a convergent transcriptional target of both inflammatory and oncogenic signals.","evidence":"Zinc finger nuclease mutagenesis in zebrafish; chemical epistasis; ChIP for c-Jun and KLF6; validation in human myeloid cells and leukemia models","pmids":["23539630","24130502"],"confidence":"High","gaps":["Direct c-Jun binding site on ALOX5 promoter not mapped in human cells","Whether KLF6 cooperates with Sp1/Egr1 tandem-repeat elements unclear"]},{"year":2014,"claim":"ALOX5 was identified as a mediator of stress-induced Alzheimer's-like tauopathy: genetic deletion in 3xTg AD mice prevents stress-induced tau hyperphosphorylation, GSK3β activation, LTP impairment, and memory deficits.","evidence":"3xTg/5LO−/− mice; restraint/isolation stress; LTP electrophysiology; fear conditioning; phospho-tau/GSK3β Western blot","pmids":["25122659"],"confidence":"Medium","gaps":["Which ALOX5-derived lipid mediator activates GSK3β not identified","Not replicated in an independent AD mouse model","Human relevance not established"]},{"year":2016,"claim":"ALOX5 was shown to mediate JAK2V617F-driven polycythemia vera through AKT activation and β-catenin maintenance, extending the CML finding to a second myeloproliferative neoplasm and defining the downstream effector pathway.","evidence":"JAK2V617F PV mouse model; Alox5 KO and zileuton; colony assays from human JAK2V617F CD34+ cells; AKT/β-catenin Western blot","pmids":["27784744"],"confidence":"High","gaps":["Whether AKT activation is directly mediated by a specific leukotriene receptor is untested","Long-term HSC effects of Alox5 loss in PV not studied"]},{"year":2017,"claim":"PRC2-mediated epigenetic silencing of ALOX5 in MLL-rearranged AML was discovered, showing that ALOX5 can function as a context-dependent tumor suppressor whose restoration sensitizes leukemia cells to chemotherapy.","evidence":"ChIP for PRC2 marks at ALOX5 promoter; colony-forming and bone marrow transplantation assays; drug sensitivity assays","pmids":["28500307"],"confidence":"Medium","gaps":["Mechanism by which restored ALOX5 sensitizes to doxorubicin/cytarabine is unclear","Apparent contradiction with CML/PV role not reconciled mechanistically"]},{"year":2019,"claim":"Computational and biochemical dissection of all four triad determinants (including Ala603Ile) confirmed that mutagenesis abolishes both 5S-lipoxygenation and LTA4 synthase activity, with QM/MM modeling showing altered substrate alignment, completing the structural picture of ALOX5 specificity.","evidence":"Recombinant Sf9 expression; HPLC; stereospecifically deuterium-labeled substrates; in silico docking, MD, QM/MM","pmids":["31664810"],"confidence":"High","gaps":["No experimentally determined crystal structure of mutant active site","Dynamics of substrate entry into the pocket not characterized"]},{"year":2020,"claim":"Systematic identification of ALOX5 promoter-binding proteins revealed G-quadruplex structures in the GC-rich promoter and identified novel transcriptional regulators (KLF13, KLF16, MAZ, ZBTB7A) and G-quadruplex interactors (BLM, DHX36), expanding the regulatory landscape beyond Sp1/Egr1.","evidence":"DNA pulldown coupled to label-free quantitative mass spectrometry; circular dichroism spectroscopy; antibody-based G-quadruplex detection","pmids":["32096311"],"confidence":"Medium","gaps":["Functional validation of individual novel regulators not performed","Whether G-quadruplex structures regulate transcription in vivo is unknown"]},{"year":2021,"claim":"A PKCβ–ERK1/2–ALOX5–PTEN axis was defined as a mechanism of BCR-ABL-independent TKI resistance in CML, showing that ALOX5 inactivates PTEN downstream of ERK signaling to sustain resistance.","evidence":"shRNA knockdown; ERK inhibitors; PTEN activity assays; CML-PDX mouse model with PKCβ inhibitor","pmids":["33561320"],"confidence":"Medium","gaps":["Direct mechanism of PTEN inactivation by ALOX5 products not identified","Single lab without independent replication"]},{"year":2022,"claim":"ALOX5 was established as a caspase-9-parallel cell death executor: Erk1-dependent phosphorylation targets ALOX5 to the nuclear membrane where it mediates lipid peroxidation causing DNA damage and cell death; double knockout of caspase-9 and Alox5 causes T cell expansion in vivo, demonstrating non-redundant regulation of T cell homeostasis.","evidence":"Genome-wide siRNA screen; caspase-9/Alox5 double-KO mice; ROS/lipid peroxidation assays; subcellular imaging","pmids":["36231015"],"confidence":"High","gaps":["Identity of specific lipid peroxidation products at the nuclear membrane not determined","Whether this pathway operates in non-T cell lineages unknown"]},{"year":2022,"claim":"ERK-dependent ALOX5 activation was shown to mediate ferroptosis in neurons downstream of lysyl oxidase, linking ALOX5 to seizure-induced hippocampal neuronal death.","evidence":"AAV-based LysOX overexpression; ERK inhibitor studies; lipid peroxidation assays; seizure mouse model","pmids":["36176900"],"confidence":"Medium","gaps":["Whether ALOX5-mediated neuronal ferroptosis is ACSL4-dependent or independent not clarified","Single lab"]},{"year":2023,"claim":"ALOX5 was linked to Huntington's disease pathogenesis: polyglutamine-expanded huntingtin stabilizes FLAP, enhancing ALOX5 activity and triggering ferroptosis selectively under HD-relevant stress; Alox5 knockout ameliorates HD pathology and extends lifespan in HD mice.","evidence":"RNAi genome screen; ALOX5–FLAP co-IP and stabilization assays; neuronal ferroptosis assays; Alox5 KO in HD mouse model","pmids":["36921996"],"confidence":"High","gaps":["Mechanism by which mutant huntingtin stabilizes FLAP not fully elucidated","Whether ALOX5 inhibition benefits manifest HD not tested"]},{"year":2023,"claim":"Multiple studies established ALOX5-derived 5-HETE and LTB4 as drivers of immunosuppressive M2 macrophage polarization across cancer types, acting through JAK/STAT in pancreatic cancer, PI3K via BLT1/BLT2 in cholangiocarcinoma, and NRF2 nuclear translocation in glioma, while EGR1-dependent ALOX5 expression was shown to be required for ferroptosis sensitivity in bladder cancer.","evidence":"Lentiviral overexpression; zileuton and receptor-blocking studies; orthotopic and xenograft mouse models; CRISPR/Cas9 KO; ChIP for EGR1; oxylipin profiling","pmids":["37348233","38124204","39142719","38062004","37080437"],"confidence":"Medium","gaps":["Whether the M2-promoting and ferroptosis-promoting roles of ALOX5 are context-exclusive or coexist in a single tumor is unresolved","Relative contribution of LTB4 versus 5-HETE to immunosuppression not established in a unified system"]},{"year":2024,"claim":"A complete LTB4–ORAI3–NLRP3 pyroptosis pathway was delineated in CD4+ T cells from RA patients, showing that ALOX5-derived LTB4 triggers Ca2+ influx through ORAI3, activating NLRP3 inflammasome-mediated pyroptosis, with in vivo validation in two rodent arthritis models.","evidence":"Patient T cell analysis; ALOX5 knockdown; LTB4 ELISA; Ca2+ flux assays; ORAI3 blocking; NLRP3 activation; two rodent RA models","pmids":["38412254"],"confidence":"High","gaps":["Whether this pathway operates in other autoimmune T cell–driven diseases unknown","Structural basis of LTB4–ORAI3 interaction not defined"]},{"year":2024,"claim":"PARP-1 was identified as a post-translational stabilizer of ALOX5 through PARylation, linking DNA damage response signaling to leukotriene biosynthesis in tumor-associated neutrophils.","evidence":"Co-IP/mass spectrometry; PARylation assay; PARP-1 knockdown and inhibitor; murine tumor model","pmids":["38172525"],"confidence":"Medium","gaps":["PARylation site(s) on ALOX5 not mapped","Whether PARylation affects ALOX5 enzymatic activity or only stability not distinguished","Not replicated independently"]},{"year":null,"claim":"Key unresolved questions include: (1) how ALOX5 functions as a pro-tumorigenic factor in CML/PV while acting as a PRC2-repressed tumor suppressor in MLL-AML; (2) which specific lipid products mediate nuclear-membrane ferroptosis versus conventional leukotriene signaling; (3) the structural basis of FLAP stabilization by mutant huntingtin; and (4) whether ALOX5 promoter G-quadruplex structures regulate transcription in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["Context-dependent oncogene vs. tumor suppressor function not mechanistically reconciled","No crystal structure of ALOX5–FLAP complex","In vivo relevance of G-quadruplex promoter regulation untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[3,5,9,13]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[5,13]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[28,29]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[28,18]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[18,28]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[29]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,5,9,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,25,21,23,27]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[18,19,20,22,24,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,16,17,21,23,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,7,11,14,15,22]}],"complexes":[],"partners":["FLAP","PARP1","SP1","EGR1","KLF6","ORAI3"],"other_free_text":[]},"mechanistic_narrative":"ALOX5 encodes arachidonate 5-lipoxygenase, the enzyme that oxygenates arachidonic acid at the 5S position to produce 5(S)-HpETE and subsequently leukotrienes (LTB4, LTC4) and 5-HETE, with reaction specificity determined by a triad of residues (Phe359, Ala424, Asn425, Ala603) that define substrate orientation within the active-site pocket [PMID:23246375, PMID:31664810]. ALOX5 activity is regulated at multiple levels: transcriptionally through Sp1/Egr1 tandem-repeat promoter elements, KLF6, EGR1, PRC2-mediated repression, and LPS signaling [PMID:10369259, PMID:24130502, PMID:38062004, PMID:28500307, PMID:32120263]; post-translationally by PARP-1-mediated PARylation that stabilizes the protein, by Erk1-dependent phosphorylation that drives nuclear membrane translocation, and by FLAP cofactor stabilization [PMID:38172525, PMID:36231015, PMID:36921996]; and functionally through stimulus-dependent cytosol-to-nuclear-membrane redistribution [PMID:17484769]. Downstream, ALOX5-derived lipid mediators drive leukocyte migration via JNK/c-Jun, promote CD4+ T cell pyroptosis through an LTB4–ORAI3–NLRP3 axis, execute ferroptosis through ACSL4-independent lipid peroxidation and AMPK/mTOR–GPX4 suppression, sustain leukemia stem cell survival in CML and polycythemia vera through AKT/β-catenin signaling, regulate macrophage M2 polarization via JAK/STAT and PI3K pathways, and support pancreatic β-cell insulin secretion [PMID:23539630, PMID:38412254, PMID:36231015, PMID:37080437, PMID:19503090, PMID:27784744, PMID:37348233, PMID:38124204, PMID:18421434]."},"prefetch_data":{"uniprot":{"accession":"P09917","full_name":"Polyunsaturated fatty acid 5-lipoxygenase","aliases":["Arachidonate 5-lipoxygenase","5-LO","5-lipoxygenase"],"length_aa":674,"mass_kda":78.0,"function":"Catalyzes the oxygenation of arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) to 5-hydroperoxyeicosatetraenoate (5-HPETE) followed by the dehydration to 5,6- epoxyeicosatetraenoate (Leukotriene A4/LTA4), the first two steps in the biosynthesis of leukotrienes, which are potent mediators of inflammation (PubMed:19022417, PubMed:21233389, PubMed:22516296, PubMed:23246375, PubMed:24282679, PubMed:24893149, PubMed:31664810, PubMed:8615788, PubMed:8631361). Also catalyzes the oxygenation of arachidonate into 8-hydroperoxyicosatetraenoate (8-HPETE) and 12-hydroperoxyicosatetraenoate (12-HPETE) (PubMed:23246375). Displays lipoxin synthase activity being able to convert (15S)-HETE into a conjugate tetraene (PubMed:31664810). Although arachidonate is the preferred substrate, this enzyme can also metabolize oxidized fatty acids derived from arachidonate such as (15S)-HETE, eicosapentaenoate (EPA) such as (18R)- and (18S)-HEPE or docosahexaenoate (DHA) which lead to the formation of specialized pro-resolving mediators (SPM) lipoxin and resolvins E and D respectively, therefore it participates in anti-inflammatory responses (PubMed:17114001, PubMed:21206090, PubMed:31664810, PubMed:32404334, PubMed:32841762, PubMed:8615788). Oxidation of DHA directly inhibits endothelial cell proliferation and sprouting angiogenesis via peroxisome proliferator-activated receptor gamma (PPARgamma) (By similarity). It does not catalyze the oxygenation of linoleic acid and does not convert (5S)-HETE to lipoxin isomers (PubMed:31664810). In addition to inflammatory processes, it participates in dendritic cell migration, wound healing through an antioxidant mechanism based on heme oxygenase-1 (HO-1) regulation expression, monocyte adhesion to the endothelium via ITGAM expression on monocytes (By similarity). Moreover, it helps establish an adaptive humoral immunity by regulating primary resting B cells and follicular helper T cells and participates in the CD40-induced production of reactive oxygen species (ROS) after CD40 ligation in B cells through interaction with PIK3R1 that bridges ALOX5 with CD40 (PubMed:21200133). May also play a role in glucose homeostasis, regulation of insulin secretion and palmitic acid-induced insulin resistance via AMPK (By similarity). Can regulate bone mineralization and fat cell differentiation increases in induced pluripotent stem cells (By similarity)","subcellular_location":"Cytoplasm; Nucleus matrix; Nucleus membrane; Cytoplasm, perinuclear region; Cytoplasm, cytosol; Nucleus envelope; Nucleus intermembrane space","url":"https://www.uniprot.org/uniprotkb/P09917/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ALOX5","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ALOX5","total_profiled":1310},"omim":[{"mim_id":"621173","title":"G PROTEIN-COUPLED RECEPTOR 146; GPR146","url":"https://www.omim.org/entry/621173"},{"mim_id":"608557","title":"MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, 2","url":"https://www.omim.org/entry/608557"},{"mim_id":"608232","title":"LEUKEMIA, CHRONIC MYELOID; CML","url":"https://www.omim.org/entry/608232"},{"mim_id":"606748","title":"COACTOSIN-LIKE PROTEIN 1; COTL1","url":"https://www.omim.org/entry/606748"},{"mim_id":"606241","title":"DICER 1, RIBONUCLEASE III; DICER1","url":"https://www.omim.org/entry/606241"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":69.4},{"tissue":"lymphoid tissue","ntpm":90.4}],"url":"https://www.proteinatlas.org/search/ALOX5"},"hgnc":{"alias_symbol":["5-LOX"],"prev_symbol":[]},"alphafold":{"accession":"P09917","domains":[{"cath_id":"2.60.60.20","chopping":"4-115","consensus_level":"high","plddt":94.9491,"start":4,"end":115},{"cath_id":"1.20.245.10","chopping":"149-176_367-558_606-668","consensus_level":"medium","plddt":97.5775,"start":149,"end":668},{"cath_id":"3.10.450.60","chopping":"180-359_562-594","consensus_level":"medium","plddt":97.9318,"start":180,"end":594}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09917","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09917-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09917-F1-predicted_aligned_error_v6.png","plddt_mean":97.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ALOX5","jax_strain_url":"https://www.jax.org/strain/search?query=ALOX5"},"sequence":{"accession":"P09917","fasta_url":"https://rest.uniprot.org/uniprotkb/P09917.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09917/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09917"}},"corpus_meta":[{"pmid":"10369259","id":"PMC_10369259","title":"Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10369259","citation_count":394,"is_preprint":false},{"pmid":"19503090","id":"PMC_19503090","title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19503090","citation_count":249,"is_preprint":false},{"pmid":"15637091","id":"PMC_15637091","title":"Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.","date":"2005","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/15637091","citation_count":129,"is_preprint":false},{"pmid":"29883727","id":"PMC_29883727","title":"Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach.","date":"2018","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29883727","citation_count":114,"is_preprint":false},{"pmid":"34883251","id":"PMC_34883251","title":"A novel mechanism linking ferroptosis and endoplasmic reticulum stress via the circPtpn14/miR-351-5p/5-LOX signaling in melatonin-mediated treatment of traumatic brain injury.","date":"2021","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34883251","citation_count":92,"is_preprint":false},{"pmid":"15566290","id":"PMC_15566290","title":"New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.","date":"2004","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15566290","citation_count":87,"is_preprint":false},{"pmid":"18033773","id":"PMC_18033773","title":"Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18033773","citation_count":84,"is_preprint":false},{"pmid":"12005204","id":"PMC_12005204","title":"The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.","date":"2002","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/12005204","citation_count":83,"is_preprint":false},{"pmid":"36921996","id":"PMC_36921996","title":"ALOX5-mediated ferroptosis acts as a distinct cell death pathway upon oxidative stress in Huntington's disease.","date":"2023","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/36921996","citation_count":81,"is_preprint":false},{"pmid":"21669192","id":"PMC_21669192","title":"Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.","date":"2011","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21669192","citation_count":79,"is_preprint":false},{"pmid":"18174194","id":"PMC_18174194","title":"ALOX5 variants associated with susceptibility to human pulmonary tuberculosis.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18174194","citation_count":77,"is_preprint":false},{"pmid":"30081353","id":"PMC_30081353","title":"1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity.","date":"2018","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30081353","citation_count":59,"is_preprint":false},{"pmid":"30265377","id":"PMC_30265377","title":"Frontline Science: Reprogramming COX-2, 5-LOX, and CYP4A-mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis.","date":"2018","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/30265377","citation_count":56,"is_preprint":false},{"pmid":"21885812","id":"PMC_21885812","title":"Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.","date":"2011","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/21885812","citation_count":56,"is_preprint":false},{"pmid":"28786533","id":"PMC_28786533","title":"MiR-216a-3p inhibits colorectal cancer cell proliferation through direct targeting COX-2 and ALOX5.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28786533","citation_count":55,"is_preprint":false},{"pmid":"23539630","id":"PMC_23539630","title":"Cannabinoid receptor 2 suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5 pathway.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23539630","citation_count":55,"is_preprint":false},{"pmid":"16364163","id":"PMC_16364163","title":"ALOX5 promoter genotype, asthma severity and LTC production by eosinophils.","date":"2006","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/16364163","citation_count":54,"is_preprint":false},{"pmid":"29763636","id":"PMC_29763636","title":"Inhibition of COX-2/mPGES-1 and 5-LOX in macrophages by leonurine ameliorates monosodium urate crystal-induced inflammation.","date":"2018","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29763636","citation_count":54,"is_preprint":false},{"pmid":"37348233","id":"PMC_37348233","title":"The ALOX5 inhibitor Zileuton regulates tumor-associated macrophage M2 polarization by JAK/STAT and inhibits pancreatic cancer invasion and metastasis.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37348233","citation_count":52,"is_preprint":false},{"pmid":"18339529","id":"PMC_18339529","title":"ALOX5 promoter genotype and response to montelukast in moderate persistent asthma.","date":"2008","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18339529","citation_count":51,"is_preprint":false},{"pmid":"19823023","id":"PMC_19823023","title":"The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19823023","citation_count":50,"is_preprint":false},{"pmid":"29808459","id":"PMC_29808459","title":"mPGES-1 and ALOX5/-15 in tumor-associated macrophages.","date":"2018","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29808459","citation_count":48,"is_preprint":false},{"pmid":"18369664","id":"PMC_18369664","title":"Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease.","date":"2008","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18369664","citation_count":48,"is_preprint":false},{"pmid":"18421434","id":"PMC_18421434","title":"Identification of ALOX5 as a gene regulating adiposity and pancreatic function.","date":"2008","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/18421434","citation_count":48,"is_preprint":false},{"pmid":"28865292","id":"PMC_28865292","title":"Pyrazole-hydrazone derivatives as anti-inflammatory agents: Design, synthesis, biological evaluation, COX-1,2/5-LOX inhibition and docking study.","date":"2017","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28865292","citation_count":48,"is_preprint":false},{"pmid":"11016533","id":"PMC_11016533","title":"Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats.","date":"2000","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/11016533","citation_count":47,"is_preprint":false},{"pmid":"39224598","id":"PMC_39224598","title":"Elucidating the role of tumor-associated ALOX5+ mast cells with transformative function in cervical cancer progression via single-cell RNA sequencing.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39224598","citation_count":46,"is_preprint":false},{"pmid":"38062004","id":"PMC_38062004","title":"ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38062004","citation_count":46,"is_preprint":false},{"pmid":"12911785","id":"PMC_12911785","title":"Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population.","date":"2003","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12911785","citation_count":46,"is_preprint":false},{"pmid":"26707712","id":"PMC_26707712","title":"Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26707712","citation_count":45,"is_preprint":false},{"pmid":"37080437","id":"PMC_37080437","title":"ALOX5 promotes autophagy-dependent ferroptosis by activating the AMPK/mTOR pathway in melanoma.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37080437","citation_count":44,"is_preprint":false},{"pmid":"28238167","id":"PMC_28238167","title":"Effects of COX1-2/5-LOX blockade in Alzheimer transgenic 3xTg-AD mice.","date":"2017","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/28238167","citation_count":44,"is_preprint":false},{"pmid":"17305571","id":"PMC_17305571","title":"COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy.","date":"2007","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17305571","citation_count":42,"is_preprint":false},{"pmid":"34479036","id":"PMC_34479036","title":"Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34479036","citation_count":38,"is_preprint":false},{"pmid":"36176900","id":"PMC_36176900","title":"Critical involvement of lysyl oxidase in seizure-induced neuronal damage through ERK-Alox5-dependent ferroptosis and its therapeutic implications.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/36176900","citation_count":36,"is_preprint":false},{"pmid":"16361798","id":"PMC_16361798","title":"Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population.","date":"2005","source":"Journal of Korean medical science","url":"https://pubmed.ncbi.nlm.nih.gov/16361798","citation_count":36,"is_preprint":false},{"pmid":"16278051","id":"PMC_16278051","title":"5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease.","date":"2005","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/16278051","citation_count":36,"is_preprint":false},{"pmid":"34121352","id":"PMC_34121352","title":"ALOX5-5-HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation.","date":"2021","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34121352","citation_count":35,"is_preprint":false},{"pmid":"28500307","id":"PMC_28500307","title":"ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28500307","citation_count":34,"is_preprint":false},{"pmid":"26429877","id":"PMC_26429877","title":"Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26429877","citation_count":33,"is_preprint":false},{"pmid":"25122659","id":"PMC_25122659","title":"Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer's disease.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25122659","citation_count":33,"is_preprint":false},{"pmid":"22484053","id":"PMC_22484053","title":"Evaluation of Cissus quadrangularis extracts as an inhibitor of COX, 5-LOX, and proinflammatory mediators.","date":"2012","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22484053","citation_count":33,"is_preprint":false},{"pmid":"23600541","id":"PMC_23600541","title":"ALOX5 polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma.","date":"2013","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23600541","citation_count":31,"is_preprint":false},{"pmid":"21296957","id":"PMC_21296957","title":"ALOX5 gene variants affect eicosanoid production and response to fish oil supplementation.","date":"2011","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/21296957","citation_count":29,"is_preprint":false},{"pmid":"34517113","id":"PMC_34517113","title":"Licofelone, a potent COX/5-LOX inhibitor and a novel option for treatment of neurological disorders.","date":"2021","source":"Prostaglandins & other lipid mediators","url":"https://pubmed.ncbi.nlm.nih.gov/34517113","citation_count":29,"is_preprint":false},{"pmid":"32330842","id":"PMC_32330842","title":"Conjugated linoleic acid attenuates 2,4-dinitrofluorobenzene-induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-κB signaling.","date":"2020","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32330842","citation_count":29,"is_preprint":false},{"pmid":"34417262","id":"PMC_34417262","title":"LTB4-Driven Inflammation and Increased Expression of ALOX5/ACE2 During Severe COVID-19 in Individuals With Diabetes.","date":"2021","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/34417262","citation_count":28,"is_preprint":false},{"pmid":"38412254","id":"PMC_38412254","title":"ALOX5 drives the pyroptosis of CD4+ T cells and tissue inflammation in rheumatoid arthritis.","date":"2024","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/38412254","citation_count":28,"is_preprint":false},{"pmid":"17333352","id":"PMC_17333352","title":"Inhibitory activities and attenuated expressions of 5-LOX with red ginseng in Helicobacter pylori-infected gastric epithelial cells.","date":"2007","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17333352","citation_count":28,"is_preprint":false},{"pmid":"26122769","id":"PMC_26122769","title":"Structure Based Library Design (SBLD) for new 1,4-dihydropyrimidine scaffold as simultaneous COX-1/COX-2 and 5-LOX inhibitors.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26122769","citation_count":28,"is_preprint":false},{"pmid":"29383971","id":"PMC_29383971","title":"Evaluation of the oxidative stress-related genes ALOX5, ALOX5AP, GPX1, GPX3 and MPO for contribution to the risk of type 2 diabetes mellitus in the Han Chinese population.","date":"2018","source":"Diabetes & vascular disease research","url":"https://pubmed.ncbi.nlm.nih.gov/29383971","citation_count":28,"is_preprint":false},{"pmid":"26944113","id":"PMC_26944113","title":"Arachidonate 5-lipoxygenase (ALOX5) gene polymorphism is associated with Alzheimer's disease and body mass index.","date":"2016","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26944113","citation_count":28,"is_preprint":false},{"pmid":"17484769","id":"PMC_17484769","title":"Expression of 5-lipoxygenase (5-LOX) in T lymphocytes.","date":"2007","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17484769","citation_count":28,"is_preprint":false},{"pmid":"19553698","id":"PMC_19553698","title":"Convergence of the 5-LOX and COX-2 pathways: heme-catalyzed cleavage of the 5S-HETE-derived di-endoperoxide into aldehyde fragments.","date":"2009","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19553698","citation_count":27,"is_preprint":false},{"pmid":"23246375","id":"PMC_23246375","title":"Conversion of pro-inflammatory murine Alox5 into an anti-inflammatory 15S-lipoxygenating enzyme by multiple mutations of sequence determinants.","date":"2012","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/23246375","citation_count":27,"is_preprint":false},{"pmid":"21993002","id":"PMC_21993002","title":"Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.","date":"2011","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/21993002","citation_count":26,"is_preprint":false},{"pmid":"18280718","id":"PMC_18280718","title":"Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors.","date":"2008","source":"Prostaglandins, leukotrienes, and essential fatty acids","url":"https://pubmed.ncbi.nlm.nih.gov/18280718","citation_count":26,"is_preprint":false},{"pmid":"28821715","id":"PMC_28821715","title":"Invasive trophoblast promote stromal fibroblast decidualization via Profilin 1 and ALOX5.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28821715","citation_count":25,"is_preprint":false},{"pmid":"33224971","id":"PMC_33224971","title":"Aberrant ALOX5 Activation Correlates with HER2 Status and Mediates Breast Cancer Biological Activities through Multiple Mechanisms.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/33224971","citation_count":25,"is_preprint":false},{"pmid":"20667741","id":"PMC_20667741","title":"Design, synthesis, and biological evaluation of prenylated chalcones as 5-LOX inhibitors.","date":"2010","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20667741","citation_count":25,"is_preprint":false},{"pmid":"32971106","id":"PMC_32971106","title":"Acetyl-11-keto-β-boswellic acid prevents testicular torsion/detorsion injury in rats by modulating 5-LOX/LTB4 and p38-MAPK/JNK/Bax/Caspase-3 pathways.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32971106","citation_count":25,"is_preprint":false},{"pmid":"24130502","id":"PMC_24130502","title":"Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24130502","citation_count":24,"is_preprint":false},{"pmid":"29602046","id":"PMC_29602046","title":"Synthesis, anti-inflammatory screening, molecular docking, and COX-1,2/-5-LOX inhibition profile of some novel quinoline derivatives.","date":"2018","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29602046","citation_count":24,"is_preprint":false},{"pmid":"37913569","id":"PMC_37913569","title":"Caffeic acid modulates activation of neutrophils and attenuates sepsis-induced organ injury by inhibiting 5-LOX/LTB4 pathway.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37913569","citation_count":24,"is_preprint":false},{"pmid":"23771412","id":"PMC_23771412","title":"The selective 5-LOX inhibitor 11-keto-β-boswellic acid protects against myocardial ischemia reperfusion injury in rats: involvement of redox and inflammatory cascades.","date":"2013","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23771412","citation_count":23,"is_preprint":false},{"pmid":"21643005","id":"PMC_21643005","title":"A novel positive feedback loop involving FASN/p-ERK1/2/5-LOX/LTB4/FASN sustains high growth of breast cancer cells.","date":"2011","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/21643005","citation_count":22,"is_preprint":false},{"pmid":"18561999","id":"PMC_18561999","title":"5-LOX, 12-LOX and 15-LOX in immature forms of human leukemic blasts.","date":"2008","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/18561999","citation_count":21,"is_preprint":false},{"pmid":"38124204","id":"PMC_38124204","title":"ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38124204","citation_count":20,"is_preprint":false},{"pmid":"33561320","id":"PMC_33561320","title":"PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.","date":"2021","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33561320","citation_count":20,"is_preprint":false},{"pmid":"25721704","id":"PMC_25721704","title":"Variants in ALOX5, ALOX5AP and LTA4H are not associated with atherosclerotic plaque phenotypes: the Athero-Express Genomics Study.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25721704","citation_count":20,"is_preprint":false},{"pmid":"29041000","id":"PMC_29041000","title":"Genetic Variations of Oxidative Stress Related Genes ALOX5, ALOX5AP and MPO Modulate Ischemic Stroke Susceptibility Through Main Effects and Epistatic Interactions in a Chinese Population.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29041000","citation_count":20,"is_preprint":false},{"pmid":"15894291","id":"PMC_15894291","title":"Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.","date":"2005","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15894291","citation_count":20,"is_preprint":false},{"pmid":"30521849","id":"PMC_30521849","title":"5-Lipoxygenase (ALOX5): Genetic susceptibility to type 2 diabetes and vitamin D effects on monocytes.","date":"2018","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30521849","citation_count":19,"is_preprint":false},{"pmid":"26456699","id":"PMC_26456699","title":"The lipoxygenase pathway in zebrafish. Expression and characterization of zebrafish ALOX5 and comparison with its human ortholog.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26456699","citation_count":19,"is_preprint":false},{"pmid":"22128029","id":"PMC_22128029","title":"A high-fat diet induces bone loss in mice lacking the Alox5 gene.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22128029","citation_count":18,"is_preprint":false},{"pmid":"28451886","id":"PMC_28451886","title":"5-LOX in Alzheimer's Disease: Potential Serum Marker and In Vitro Evidences for Rescue of Neurotoxicity by Its Inhibitor YWCS.","date":"2017","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28451886","citation_count":18,"is_preprint":false},{"pmid":"39142719","id":"PMC_39142719","title":"ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia/macrophages.","date":"2024","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39142719","citation_count":17,"is_preprint":false},{"pmid":"17115186","id":"PMC_17115186","title":"TagSNP evaluation for the association of 42 inflammation loci and vascular disease: evidence of IL6, FGB, ALOX5, NFKBIA, and IL4R loci effects.","date":"2006","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17115186","citation_count":17,"is_preprint":false},{"pmid":"26959713","id":"PMC_26959713","title":"Copy number variation in ALOX5 and PTGER1 is associated with NSAIDs-induced urticaria and/or angioedema.","date":"2016","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/26959713","citation_count":17,"is_preprint":false},{"pmid":"20011686","id":"PMC_20011686","title":"Cardioprotective effect of 5-lipoxygenase gene (ALOX5) silencing in ischemia-reperfusion.","date":"2009","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/20011686","citation_count":16,"is_preprint":false},{"pmid":"27293987","id":"PMC_27293987","title":"Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice.","date":"2016","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27293987","citation_count":16,"is_preprint":false},{"pmid":"34677413","id":"PMC_34677413","title":"Knock-In Mice Expressing a 15-Lipoxygenating Alox5 Mutant Respond Differently to Experimental Inflammation Than Reported Alox5 Mice.","date":"2021","source":"Metabolites","url":"https://pubmed.ncbi.nlm.nih.gov/34677413","citation_count":16,"is_preprint":false},{"pmid":"36605525","id":"PMC_36605525","title":"Interference of ALOX5 alleviates inflammation and fibrosis in high glucose‑induced renal mesangial cells.","date":"2022","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36605525","citation_count":15,"is_preprint":false},{"pmid":"32096311","id":"PMC_32096311","title":"Analysis of proximal ALOX5 promoter binding proteins by quantitative proteomics.","date":"2020","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/32096311","citation_count":15,"is_preprint":false},{"pmid":"32120263","id":"PMC_32120263","title":"LPS induces ALOX5 promoter activation and 5-lipoxygenase expression in human monocytic cells.","date":"2020","source":"Prostaglandins, leukotrienes, and essential fatty acids","url":"https://pubmed.ncbi.nlm.nih.gov/32120263","citation_count":15,"is_preprint":false},{"pmid":"27231478","id":"PMC_27231478","title":"Virtual Dual inhibition of COX-2 / 5-LOX enzymes based on binding properties of alpha-amyrins, the anti-inflammatory compound as a promising anti-cancer drug.","date":"2016","source":"EXCLI journal","url":"https://pubmed.ncbi.nlm.nih.gov/27231478","citation_count":15,"is_preprint":false},{"pmid":"38172525","id":"PMC_38172525","title":"Cancer-educated neutrophils promote lung cancer progression via PARP-1-ALOX5-mediated MMP-9 expression.","date":"2024","source":"Cancer biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38172525","citation_count":14,"is_preprint":false},{"pmid":"33369192","id":"PMC_33369192","title":"CaMKIIγ regulates the viability and self-renewal of acute myeloid leukaemia stem-like cells by the Alox5/NF-κB pathway.","date":"2020","source":"International journal of laboratory hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33369192","citation_count":14,"is_preprint":false},{"pmid":"31664810","id":"PMC_31664810","title":"Mutations of Triad Determinants Changes the Substrate Alignment at the Catalytic Center of Human ALOX5.","date":"2019","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/31664810","citation_count":14,"is_preprint":false},{"pmid":"33923148","id":"PMC_33923148","title":"Polyphenolic Profile of Callistemon viminalis Aerial Parts: Antioxidant, Anticancer and In Silico 5-LOX Inhibitory Evaluations.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33923148","citation_count":14,"is_preprint":false},{"pmid":"36786721","id":"PMC_36786721","title":"Exosomes derived from human adipose-derived stem cells alleviate hepatic ischemia-reperfusion (I/R) injury through the miR-183/ALOX5 axis.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/36786721","citation_count":14,"is_preprint":false},{"pmid":"31918059","id":"PMC_31918059","title":"Effects of ALOX5, IL6R and SFTPD gene polymorphisms on the risk of lung cancer: A case-control study in China.","date":"2020","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31918059","citation_count":13,"is_preprint":false},{"pmid":"38340032","id":"PMC_38340032","title":"Magnolin alleviated DSS-induced colitis by inhibiting ALOX5-mediated ferroptosis.","date":"2024","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38340032","citation_count":13,"is_preprint":false},{"pmid":"23067353","id":"PMC_23067353","title":"Association of Sp1 tandem repeat polymorphism of ALOX5 with coronary artery disease in Indian subjects.","date":"2012","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/23067353","citation_count":13,"is_preprint":false},{"pmid":"39278904","id":"PMC_39278904","title":"Multiomics integrated analysis and experimental validation identify TLR4 and ALOX5 as oxidative stress-related biomarkers in intracranial aneurysms.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39278904","citation_count":12,"is_preprint":false},{"pmid":"36231015","id":"PMC_36231015","title":"Mitochondrion-Mediated Cell Death through Erk1-Alox5 Independent of Caspase-9 Signaling.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36231015","citation_count":12,"is_preprint":false},{"pmid":"37955689","id":"PMC_37955689","title":"Hederagenin protects against myocardial ischemia-reperfusion injury via attenuating ALOX5-mediated ferroptosis.","date":"2023","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37955689","citation_count":12,"is_preprint":false},{"pmid":"25193960","id":"PMC_25193960","title":"Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia.","date":"2014","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/25193960","citation_count":12,"is_preprint":false},{"pmid":"27784744","id":"PMC_27784744","title":"Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27784744","citation_count":12,"is_preprint":false},{"pmid":"39068603","id":"PMC_39068603","title":"Quercetin Alleviates LPS-Stimulated Myocardial Injury through Regulating ALOX5/PI3K/AKT Pathway in Sepsis.","date":"2024","source":"Cardiovascular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/39068603","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56477,"output_tokens":8139,"usd":0.145758},"stage2":{"model":"claude-opus-4-6","input_tokens":11908,"output_tokens":5474,"usd":0.294585},"total_usd":0.440343,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"The ALOX5 core promoter contains a variable number of Sp1/Egr1-binding tandem repeats; variants with other than five repeats show diminished promoter-reporter activity in tissue culture, leading to reduced ALOX5 transcription and decreased leukotriene production, which predicts differential clinical response to ALOX5-pathway modifiers in asthma.\",\n      \"method\": \"Promoter-reporter (luciferase) assay in tissue culture; pharmacogenetic clinical association study\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional promoter assay plus clinical pharmacogenetic validation; widely replicated across multiple subsequent studies\",\n      \"pmids\": [\"10369259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Eosinophils bearing the ALOX5 promoter non5/non5 genotype express less ALOX5 mRNA and produce less LTC4 than those with the 5/5 genotype, directly linking the tandem-repeat polymorphism to reduced enzyme expression and leukotriene output in primary human cells.\",\n      \"method\": \"In vitro eosinophil culture; RT-PCR for ALOX5 mRNA; LTC4 ELISA; genotyping\",\n      \"journal\": \"Allergy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional measurement in primary cells from genotyped donors; single lab\",\n      \"pmids\": [\"16364163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Alox5 is required for BCR-ABL-induced chronic myeloid leukemia (CML) in mice; loss of Alox5 impairs differentiation, cell division, and survival of long-term leukemia stem cells (LT-LSCs) without significantly affecting normal hematopoietic stem cells, preventing CML development.\",\n      \"method\": \"Alox5 knockout mouse model; BCR-ABL bone marrow transplantation CML model; colony-forming and replating assays; flow cytometry for LSC populations; pharmacological inhibition with zileuton\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function in vivo with specific cellular phenotype; replicated with pharmacological inhibitor; highly cited foundational paper\",\n      \"pmids\": [\"19503090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The 5-lipoxygenase product 5S-HETE is oxygenated by COX-2 to yield a bicyclic di-endoperoxide; heme (hematin or ferrous iron) catalyzes cleavage of both peroxide O–O bonds to generate 4S-HNE, 8-oxo-5S-hydroxy-6E-octenoic acid, and malondialdehyde, identifying a convergent ALOX5/COX-2 pathway that produces canonical lipid peroxidation products.\",\n      \"method\": \"In vitro enzymatic assay with purified hematin/ferrous chloride; HPLC product analysis; chiral-phase HPLC for stereochemical assignment\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with product characterization and stereochemical validation\",\n      \"pmids\": [\"19553698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ALOX5 inhibition with zileuton or knockdown of Alox5 expression reduces ALOX5 activity and impairs insulin secretion in pancreatic islets; Alox5-/- mice show increased fat mass, impaired glucose-stimulated insulin secretion, and decreased insulin/PDX1 gene expression; siRNA knockdown of ALOX5 in human islets phenocopies this, demonstrating a direct role for 5-LO in pancreatic beta-cell function.\",\n      \"method\": \"Alox5 knockout mice; in vivo glucose tolerance tests; isolated islet insulin secretion assays; siRNA knockdown in human islets; RT-PCR for insulin and PDX1\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO and siRNA in human islets with orthogonal functional readouts; published as independent replication of mouse and human findings\",\n      \"pmids\": [\"18421434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Reduction of the substrate-binding pocket volume of mouse Alox5 by multiple mutations (Phe359Trp + Ala424Ile + Asn425Met) converts it from a 5-lipoxygenating enzyme to a dominant 15S-lipoxygenating enzyme; the same triad mutations in human ALOX5 yield the same result, establishing that pocket geometry determines reaction specificity.\",\n      \"method\": \"Site-directed mutagenesis; recombinant enzyme expression; HPLC product analysis; structural modeling\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis and product characterization; confirmed in both mouse and human enzyme\",\n      \"pmids\": [\"23246375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cannabinoid receptor 2 (Cnr2) activation suppresses leukocyte inflammatory migration by downregulating Alox5 expression through inhibition of the JNK/c-Jun signaling axis; alox5 is a direct transcriptional target of c-Jun; genetic inactivation of Alox5 blocks leukocyte migration in zebrafish, establishing a Cnr2–JNK–c-Jun–Alox5 pathway.\",\n      \"method\": \"Chemical genetic screen in zebrafish; zinc finger nuclease-mediated Cnr2 and Alox5 mutagenesis; leukocyte migration assays; JNK/c-Jun inhibitor studies; human myeloid cell validation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in zebrafish with mechanistic follow-up in human cells; multiple orthogonal methods\",\n      \"pmids\": [\"23539630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RUNX1-ETO9a upregulates Alox5 via the C2H2 zinc finger transcription factor KLF6; KLF6 is required for Alox5 induction by RUNX1-ETO9a, and KLF6 is specifically upregulated by RUNX1-ETO in human leukemia cells; loss of Alox5 reduces activity of RUNX1-ETO9a, MLL-AF9, and PML-RARα in vitro.\",\n      \"method\": \"ChIP assays; loss-of-function (shRNA/KO) in leukemia cell models; bone marrow transplantation assay; colony-forming assay\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis and ChIP in leukemia models; single lab but multiple approaches\",\n      \"pmids\": [\"24130502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Genetic deletion of ALOX5 in triple-transgenic Alzheimer's disease mice (3xTg/5LO-/-) prevents stress-induced tau hyperphosphorylation, increased GSK3β activity, long-term potentiation impairment, and fear-conditioned memory deficits caused by restraint/isolation stress, establishing that ALOX5 mediates stress-dependent propagation of Alzheimer's-like tauopathy.\",\n      \"method\": \"Genetic knockout (3xTg/5LO-/-); restraint/isolation stress paradigm; LTP electrophysiology; fear-conditioning behavior; Western blot for phospho-tau and GSK3β\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined electrophysiological and behavioral phenotype; single lab\",\n      \"pmids\": [\"25122659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Zebrafish ALOX2 is a functional ortholog of human ALOX5: it oxygenates arachidonic acid at the 5S position and also exhibits leukotriene synthase activity; triad determinant mutagenesis (Phe359Trp, Ala424Ile, Asn425Met) shifts reaction specificity from 5S- to dominant 15S-lipoxygenation, confirming that the same catalytic determinants govern positional specificity in both vertebrate orthologs.\",\n      \"method\": \"Recombinant expression in pro- and eukaryotic systems; HPLC product analysis; site-directed mutagenesis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis confirming catalytic mechanism\",\n      \"pmids\": [\"26456699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"JAK2V617F strongly upregulates Alox5 expression in hematopoietic cells; genetic deletion or pharmacological inhibition of Alox5 attenuates polycythemia vera (PV) development in mice by inducing cell-cycle arrest and apoptosis in PV cells and suppressing PV-initiating cells; mechanistically, Alox5 inhibition reduces AKT activation and decreases β-catenin expression in JAK2V617F-expressing cells.\",\n      \"method\": \"JAK2V617F PV mouse model; Alox5 knockout; zileuton pharmacological inhibition; colony formation from human JAK2V617F CD34+ cells; Western blot for AKT and β-catenin\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological inhibition with defined molecular mechanism; validated in human CD34+ cells\",\n      \"pmids\": [\"27784744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ALOX5 is transcriptionally repressed in MLL-rearranged AML via Polycomb repressive complex 2 (PRC2); restoration of Alox5 expression sensitizes MLL-rearranged leukemic cells to doxorubicin and cytarabine, with Stat and K-Ras signaling pathways negatively correlated with Alox5 overexpression.\",\n      \"method\": \"Affymetrix microarray; ChIP assay for PRC2; colony-forming and bone marrow transplantation assays; drug sensitivity assays in vitro and in vivo\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirming PRC2-mediated repression plus functional rescue experiments in vivo; single lab\",\n      \"pmids\": [\"28500307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Profilin 1 (PFN1) secreted by invasive extravillous trophoblasts induces decidualization of human endometrial stromal cells and downregulates ALOX5 expression in these stromal cells and in THP-1 macrophages, identifying a PFN1–ALOX5 signaling axis in decidualization during early pregnancy.\",\n      \"method\": \"Primary human endometrial stromal cell culture; recombinant PFN1 treatment; Western blot and qPCR for ALOX5; immunolocalization of ALOX5 in first-trimester decidua\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional cell-based assay with protein localization; single lab, moderate follow-up\",\n      \"pmids\": [\"28821715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Mutagenesis of the triad determinants (Phe359Trp/Ala424Ile/Asn425Met/Ala603Ile) in human ALOX5 abolishes its 5S-lipoxygenating and leukotriene synthase activity, instead producing 15(S)- and 8(S)-HpETE; structural docking, molecular dynamics, and QM/MM calculations confirm that these mutations alter substrate orientation within the active site cavity, linking pocket geometry to reaction specificity.\",\n      \"method\": \"Recombinant expression in Sf9 insect cells; HPLC product characterization; kinetic studies with stereospecifically deuterium-labeled substrates; in silico docking, MD simulation, QM/MM\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis, product characterization, stereochemical probes, and computational validation\",\n      \"pmids\": [\"31664810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Mass spectrometric DNA pulldown of the ALOX5 proximal promoter identified 66 specific binding proteins; key transcriptional regulators include known factors Sp1, Sp3, and Sp2, Krüppel-like factors KLF13 and KLF16, and zinc finger proteins MAZ, PRDM10, VEZF1, ZBTB7A, ZNF281, ZNF579; helicases BLM and DHX36, and hnRNPD/hnRNPK (G-quadruplex interactors) were also identified; spectroscopic and antibody methods confirmed that the GC-rich ALOX5 promoter forms DNA G-quadruplex structures that may regulate transcription.\",\n      \"method\": \"DNA pulldown coupled to label-free quantitative mass spectrometry; circular dichroism spectroscopy; antibody-based G-quadruplex detection\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic proteomics pulldown with orthogonal structural confirmation; single lab\",\n      \"pmids\": [\"32096311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LPS activates the ALOX5 promoter and increases 5-LO mRNA and protein expression in human monocytic cells (MM1, THP-1); LPS and TGF-β synergistically increase 5-LO product biosynthesis; LPS-driven ALOX5 promoter activation does not affect LTA4 metabolism, indicating LPS specifically upregulates early steps of leukotriene biosynthesis.\",\n      \"method\": \"ALOX5 promoter-luciferase reporter assay; RT-PCR and Western blot for 5-LO; HPLC-based 5-LO product measurement\",\n      \"journal\": \"Prostaglandins, leukotrienes, and essential fatty acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay plus functional leukotriene biosynthesis measurement; single lab\",\n      \"pmids\": [\"32120263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PKC-β overexpression drives BCR-ABL-independent TKI resistance in CML by upregulating Alox5 through ERK1/2 signaling; Alox5 in turn inactivates PTEN, sustaining TKI insensitivity; inhibition of PKC-β restores imatinib sensitivity in CD34+ CML cells and prolongs survival in a CML-PDX mouse model.\",\n      \"method\": \"shRNA knockdown; gene expression profiling (84-gene leukemia array); ERK1/2 pathway inhibitors; PTEN activity assays; in vivo PDX model with PKC-β inhibitor LY333531\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established in cell lines and PDX with mechanistic follow-up; single lab\",\n      \"pmids\": [\"33561320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ALOX5 produces 5-HETE from arachidonic acid in gastric cancer cells; ALOX5 overexpression or exogenous 5-HETE activates MEK/ERK signaling to promote gastric cancer cell growth and reduce chemotherapy sensitivity, while ALOX5 inhibition suppresses ERK activation and sensitizes cells to chemotherapy.\",\n      \"method\": \"ALOX5 overexpression and pharmacological inhibition; phospho-ERK Western blot; cell growth and survival assays; 5-HETE ELISA\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function and loss-of-function with defined pathway readout; single lab\",\n      \"pmids\": [\"34121352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Erk1-dependent phosphorylation of Alox5 targets it to the nuclear membrane where it mediates lipid peroxidation; resulting nuclear translocation of cytolytic molecules causes DNA damage and cell death independently of caspase-9; double knockout of caspase-9 and Alox5 in mice causes significant T cell expansion, demonstrating that these pathways function in parallel to regulate T cell death in vivo.\",\n      \"method\": \"Genome-wide siRNA library screen; caspase-9/Alox5 double-knockout mice; ROS and lipid peroxidation assays; subcellular fractionation/imaging; T cell proliferation/apoptosis assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — unbiased genome-wide screen followed by genetic double-KO validation in vivo with mechanistic imaging/biochemical readouts\",\n      \"pmids\": [\"36231015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LysOX promotes ferroptosis-associated lipid peroxidation in neurons via ERK-dependent activation of Alox5 (5-lipoxygenase) signaling; AAV-mediated LysOX overexpression enhances ferroptosis sensitivity and seizure-induced hippocampal damage, while pharmacological LysOX inhibition blocks seizure-induced Alox5-mediated ferroptosis.\",\n      \"method\": \"AAV-based LysOX overexpression in vivo; LysOX pharmacological inhibition (BAPN); ERK inhibitor studies; lipid peroxidation assays; seizure mouse model\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain- and loss-of-function with mechanistic pathway (ERK-Alox5) established; single lab\",\n      \"pmids\": [\"36176900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HTTQ94 (polyglutamine-expanded N-terminal huntingtin fragment) activates ALOX5-mediated ferroptosis by stabilizing FLAP (5-LO activating protein), an essential cofactor of ALOX5 lipoxygenase activity; ALOX5 is required for HTTQ94-induced ferroptosis in response to ROS stress and glutamate, but is dispensable for common ferroptosis inducers (e.g., erastin); Alox5 genetic inactivation ameliorates HD pathology and extends lifespan in HD mice.\",\n      \"method\": \"RNAi-mediated genome screen; ALOX5 and FLAP co-immunoprecipitation/stabilization assays; neuronal cell ferroptosis assays; Alox5 knockout in HD mice; behavioral and pathological phenotyping\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — unbiased RNAi screen, biochemical FLAP stabilization mechanism, and in vivo genetic rescue; multiple orthogonal methods\",\n      \"pmids\": [\"36921996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ALOX5 promotes macrophage M2 polarization via the JAK/STAT pathway; lentiviral ALOX5 overexpression in macrophages induces M2-like phenotype and promotes chemotaxis toward pancreatic cancer cells; zileuton inhibits these effects by blocking ALOX5, reducing tumor invasion and liver metastasis in an orthotopic pancreatic cancer mouse model.\",\n      \"method\": \"Lentiviral ALOX5 overexpression; JAK/STAT pathway inhibitors; in vitro macrophage polarization assays; orthotopic nude mouse model; survival analysis\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function in vitro and in vivo with defined JAK/STAT pathway mechanism; single lab\",\n      \"pmids\": [\"37348233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ALOX5 deficiency in bladder cancer cells permits ferroptosis escape; EGR1 transcriptionally regulates ALOX5 expression; CRISPR/Cas9 and RNAi loss-of-function confirmed that ALOX5 is required for ferroptosis sensitivity, with ALOX5-deficient high-pathological-stage bladder cancer cells showing ferroptosis resistance.\",\n      \"method\": \"CRISPR/Cas9 knockout; RNAi knockdown; RNA-seq; ferroptosis assays (lipid peroxidation, cell death); ChIP/reporter assays for EGR1-ALOX5 transcriptional regulation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO plus transcriptional mechanism; single lab\",\n      \"pmids\": [\"38062004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In intrahepatic cholangiocarcinoma, ALOX5-derived LTB4 binds BLT1/BLT2 receptors on tumor-associated macrophages (TAMs) and activates the PI3K pathway to promote M2 macrophage migration toward tumor cells; co-culture and bulk-sequencing confirmed PI3K as the key downstream pathway; combined ALOX5 inhibitor (zileuton) and CSF1R inhibitor reduced tumor volume and M2 macrophage infiltration in a xenograft model.\",\n      \"method\": \"In vitro macrophage co-culture model; LTB4 ELISA; BLT1/BLT2 receptor blocking; PI3K pathway inhibitors; bulk RNA-seq after co-culture; xenograft nude mouse model\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic in vitro and in vivo data with receptor and pathway identification; single lab\",\n      \"pmids\": [\"38124204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ALOX5 promotes autophagy-dependent ferroptosis in melanoma by activating the AMPK/mTOR pathway and inhibiting GPX4 expression; inhibition of autophagy reduces ALOX5-enhanced ferroptosis, indicating that ALOX5 and autophagy are synergistic; recombinant human ALOX5 protein exerts antitumor ferroptotic effects in a xenograft model.\",\n      \"method\": \"ALOX5 overexpression in melanoma cell lines and xenograft; AMPK/mTOR pathway analysis by Western blot; autophagy inhibitors; GPX4 expression; MDA/GSH/iron assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with defined AMPK/mTOR mechanism; in vivo validation; single lab\",\n      \"pmids\": [\"37080437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALOX5 activity in RA CD4+ T cells increases LTB4 production; LTB4 stimulates Ca2+ influx through ORAI3 channels, leading to NLRP3 inflammasome activation and pyroptosis; ALOX5 knockdown or pharmacological inhibition suppresses CD4+ T cell pyroptosis and improves symptoms in two rodent RA models.\",\n      \"method\": \"ALOX5 mRNA/protein quantification in patient T cells; ALOX5 knockdown; LTB4 ELISA; Ca2+ flux assays; ORAI3 blocking; NLRP3 inflammasome activation assays; rodent RA models\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic pathway (ALOX5→LTB4→ORAI3→NLRP3→pyroptosis) established with multiple orthogonal biochemical methods and validated in two in vivo models with patient-derived cells\",\n      \"pmids\": [\"38412254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In lung cancer-educated neutrophils, PARP-1 interacts with and PARylates (post-translationally modifies) ALOX5, stabilizing ALOX5 protein; this stabilization increases MMP-9 expression and promotes lung cancer cell invasion and tumor growth in vivo; PARP-1 knockdown or inhibition (AG14361) decreases ALOX5 expression and MMP-9 production, eliminating neutrophil-mediated cancer promotion.\",\n      \"method\": \"Co-immunoprecipitation; immunoprecipitation coupled to mass spectrometry (IP/MS); PARylation assay; gene knockdown; gelatin zymography for MMP-9; murine tumor model\",\n      \"journal\": \"Cancer biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP/MS identification of PARP-1–ALOX5 interaction with PARylation mechanism and in vivo functional validation; single lab\",\n      \"pmids\": [\"38172525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALOX5-derived 5-HETE from glioma cells promotes M2 polarization, PD-L1 expression, and migration of glioma-associated microglia/macrophages (GAMs) by facilitating nuclear translocation of NRF2; an anti-ALOX5 nanobody suppresses 5-HETE efflux, attenuates M2 GAM polarization, and reduces glioma progression; combination with anti-PD-1 shows superior anti-tumor efficacy.\",\n      \"method\": \"UHPLC-MS/MS oxylipin profiling; in vivo orthotopic glioma model with bioluminescence imaging; flow cytometry; immunofluorescence; NRF2 nuclear translocation assay; ALOX5-targeted nanobody; anti-PD-1 combination therapy\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (ALOX5→5-HETE→NRF2 nuclear translocation→M2/PD-L1) established with oxylipin profiling and in vivo rescue; single lab\",\n      \"pmids\": [\"39142719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"5-LOX is expressed in both resting peripheral blood T lymphocytes and T lymphoblastoid cell lines at the mRNA and protein level; the enzyme localizes primarily to the cytoplasm with some nuclear localization and translocates to the nuclear periphery following mitogenic stimulation; Jurkat cells, but not resting primary T cells, produce LTC4 and LTB4 upon CD3/CD28 cross-linking, and this synthesis is abolished by MK-886 and AA-861 (5-LO inhibitors), demonstrating stimulus-dependent translocation-linked enzymatic activation.\",\n      \"method\": \"RT-PCR; in situ RT-PCR; Western blot; immunofluorescence; FACS; LTC4/LTB4 synthesis assay with pharmacological inhibitors\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization linked to functional leukotriene production; multiple orthogonal methods; single lab\",\n      \"pmids\": [\"17484769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"5-LOX mRNA and protein are increased in hippocampus and cerebellum of aging rats, and the membrane/cytosol ratio of 5-LOX protein is larger in older versus younger brains, indicating that aging drives both increased ALOX5 expression and translocation/activation of the enzyme to membranes.\",\n      \"method\": \"Quantitative RT-PCR with internal standards; quantitative Western blotting; subcellular fractionation\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular fractionation demonstrating translocation linked to aging; single lab\",\n      \"pmids\": [\"11016533\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ALOX5 encodes arachidonate 5-lipoxygenase, a key enzyme that converts arachidonic acid to 5(S)-HpETE and subsequently to leukotrienes (including LTB4) and 5-HETE; its reaction specificity is determined by the geometry of triad determinants (Phe359/Ala424/Asn425/Ala603) lining the substrate-binding pocket, and its activity is regulated by nuclear/membrane translocation, by FLAP (stabilized in Huntington's disease by mutant huntingtin), by post-translational PARylation via PARP-1, and transcriptionally through Sp1/Egr1 tandem-repeat promoter elements, KLF6, PRC2, and LPS-driven signaling; downstream, ALOX5 drives leukocyte migration via JNK/c-Jun, promotes CD4+ T cell pyroptosis through LTB4–ORAI3–NLRP3, mediates ferroptosis through ACSL4-independent lipid peroxidation at the nuclear membrane via Erk1-dependent phosphorylation, supports leukemia stem cell survival in CML/PV through AKT and β-catenin, and regulates pancreatic beta-cell insulin secretion, with loss-of-function models in mice and human cells confirming these mechanistic roles.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ALOX5 encodes arachidonate 5-lipoxygenase, the enzyme that oxygenates arachidonic acid at the 5S position to produce 5(S)-HpETE and subsequently leukotrienes (LTB4, LTC4) and 5-HETE, with reaction specificity determined by a triad of residues (Phe359, Ala424, Asn425, Ala603) that define substrate orientation within the active-site pocket [PMID:23246375, PMID:31664810]. ALOX5 activity is regulated at multiple levels: transcriptionally through Sp1/Egr1 tandem-repeat promoter elements, KLF6, EGR1, PRC2-mediated repression, and LPS signaling [PMID:10369259, PMID:24130502, PMID:38062004, PMID:28500307, PMID:32120263]; post-translationally by PARP-1-mediated PARylation that stabilizes the protein, by Erk1-dependent phosphorylation that drives nuclear membrane translocation, and by FLAP cofactor stabilization [PMID:38172525, PMID:36231015, PMID:36921996]; and functionally through stimulus-dependent cytosol-to-nuclear-membrane redistribution [PMID:17484769]. Downstream, ALOX5-derived lipid mediators drive leukocyte migration via JNK/c-Jun, promote CD4+ T cell pyroptosis through an LTB4–ORAI3–NLRP3 axis, execute ferroptosis through ACSL4-independent lipid peroxidation and AMPK/mTOR–GPX4 suppression, sustain leukemia stem cell survival in CML and polycythemia vera through AKT/β-catenin signaling, regulate macrophage M2 polarization via JAK/STAT and PI3K pathways, and support pancreatic β-cell insulin secretion [PMID:23539630, PMID:38412254, PMID:36231015, PMID:37080437, PMID:19503090, PMID:27784744, PMID:37348233, PMID:38124204, PMID:18421434].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"The question of how ALOX5 transcription is regulated was addressed by identifying a variable tandem-repeat element of Sp1/Egr1 sites in the core promoter, establishing that copy-number variation at this locus controls enzyme expression and leukotriene output.\",\n      \"evidence\": \"Promoter-reporter assays in tissue culture combined with pharmacogenetic clinical association in asthma patients\",\n      \"pmids\": [\"10369259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which non-5 repeat alleles reduce transcription not fully resolved\", \"Identity of chromatin remodeling factors at the tandem-repeat locus unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Whether ALOX5 expression and subcellular distribution change with aging was answered by showing increased mRNA/protein and enhanced membrane translocation in aged rat brain, establishing that aging itself upregulates and activates ALOX5.\",\n      \"evidence\": \"Quantitative RT-PCR, Western blotting, and subcellular fractionation in young versus aged rat hippocampus and cerebellum\",\n      \"pmids\": [\"11016533\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal relationship between membrane translocation and age-related neuroinflammation not tested\", \"Human aging tissue not examined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The functional impact of promoter tandem-repeat variation in primary human cells was confirmed by showing that eosinophils homozygous for non-5 repeat alleles produce less ALOX5 mRNA and LTC4, validating the promoter polymorphism as a determinant of leukotriene biosynthetic capacity.\",\n      \"evidence\": \"RT-PCR and LTC4 ELISA in genotyped primary human eosinophils\",\n      \"pmids\": [\"16364163\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Sample size limited\", \"Whether other cell types show the same quantitative relationship is untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The question of how ALOX5 is activated in lymphocytes was addressed by demonstrating that the enzyme resides in the cytoplasm of resting T cells and translocates to the nuclear periphery upon mitogenic stimulation, coupling subcellular redistribution to leukotriene synthesis.\",\n      \"evidence\": \"Immunofluorescence, subcellular fractionation, and leukotriene synthesis assays with pharmacological inhibitors in primary T cells and Jurkat cells\",\n      \"pmids\": [\"17484769\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stimulus-specific translocation signals not identified\", \"Whether translocation requires FLAP in T cells not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"A convergent lipid peroxidation pathway was revealed when 5S-HETE (the ALOX5 product) was shown to be further oxygenated by COX-2 to yield a di-endoperoxide whose heme-catalyzed cleavage generates 4S-HNE and malondialdehyde, connecting ALOX5 to canonical oxidative damage markers.\",\n      \"evidence\": \"In vitro reconstitution with purified enzymes and heme; HPLC with chiral-phase stereochemical assignment\",\n      \"pmids\": [\"19553698\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular relevance of this convergent pathway not demonstrated in intact cells\", \"Relative contribution versus direct lipid peroxidation unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The long-standing question of whether ALOX5 is dispensable for normal hematopoiesis but essential for leukemia was answered by showing that Alox5 knockout prevents CML development by selectively eliminating leukemia stem cells while sparing normal HSCs.\",\n      \"evidence\": \"Alox5 knockout mice; BCR-ABL bone marrow transplantation CML model; colony-forming assays; zileuton validation\",\n      \"pmids\": [\"19503090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular target of ALOX5 products in LSCs not identified at this stage\", \"Whether ALOX5 inhibition eradicates established CML not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"ALOX5 was established as a regulator of pancreatic β-cell function: Alox5−/− mice show impaired glucose-stimulated insulin secretion and reduced insulin/PDX1 expression, phenocopied by siRNA in human islets, extending ALOX5 biology beyond immunity.\",\n      \"evidence\": \"Alox5 knockout mice with glucose tolerance tests; isolated islet insulin secretion assays; siRNA in human islets\",\n      \"pmids\": [\"18421434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific ALOX5 product mediates β-cell signaling is unknown\", \"Downstream signaling pathway linking 5-LO to PDX1 expression not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The structural basis of ALOX5 positional specificity was established by showing that mutagenesis of three triad determinants (Phe359Trp/Ala424Ile/Asn425Met) converts the enzyme from 5S- to dominant 15S-lipoxygenation in both mouse and human orthologs, proving that active-site pocket geometry dictates substrate oxygenation position.\",\n      \"evidence\": \"Site-directed mutagenesis of recombinant mouse and human ALOX5; HPLC product analysis; structural modeling\",\n      \"pmids\": [\"23246375\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of mutant enzyme not determined\", \"Whether these residues also control LTA4 synthase activity not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"ALOX5 was placed in a transcriptional signaling cascade for leukocyte migration: Cnr2 suppresses migration by inhibiting JNK/c-Jun-dependent ALOX5 transcription, while in AML, KLF6 is required for oncogene-driven ALOX5 upregulation, establishing ALOX5 as a convergent transcriptional target of both inflammatory and oncogenic signals.\",\n      \"evidence\": \"Zinc finger nuclease mutagenesis in zebrafish; chemical epistasis; ChIP for c-Jun and KLF6; validation in human myeloid cells and leukemia models\",\n      \"pmids\": [\"23539630\", \"24130502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct c-Jun binding site on ALOX5 promoter not mapped in human cells\", \"Whether KLF6 cooperates with Sp1/Egr1 tandem-repeat elements unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"ALOX5 was identified as a mediator of stress-induced Alzheimer's-like tauopathy: genetic deletion in 3xTg AD mice prevents stress-induced tau hyperphosphorylation, GSK3β activation, LTP impairment, and memory deficits.\",\n      \"evidence\": \"3xTg/5LO−/− mice; restraint/isolation stress; LTP electrophysiology; fear conditioning; phospho-tau/GSK3β Western blot\",\n      \"pmids\": [\"25122659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which ALOX5-derived lipid mediator activates GSK3β not identified\", \"Not replicated in an independent AD mouse model\", \"Human relevance not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"ALOX5 was shown to mediate JAK2V617F-driven polycythemia vera through AKT activation and β-catenin maintenance, extending the CML finding to a second myeloproliferative neoplasm and defining the downstream effector pathway.\",\n      \"evidence\": \"JAK2V617F PV mouse model; Alox5 KO and zileuton; colony assays from human JAK2V617F CD34+ cells; AKT/β-catenin Western blot\",\n      \"pmids\": [\"27784744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AKT activation is directly mediated by a specific leukotriene receptor is untested\", \"Long-term HSC effects of Alox5 loss in PV not studied\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"PRC2-mediated epigenetic silencing of ALOX5 in MLL-rearranged AML was discovered, showing that ALOX5 can function as a context-dependent tumor suppressor whose restoration sensitizes leukemia cells to chemotherapy.\",\n      \"evidence\": \"ChIP for PRC2 marks at ALOX5 promoter; colony-forming and bone marrow transplantation assays; drug sensitivity assays\",\n      \"pmids\": [\"28500307\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which restored ALOX5 sensitizes to doxorubicin/cytarabine is unclear\", \"Apparent contradiction with CML/PV role not reconciled mechanistically\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Computational and biochemical dissection of all four triad determinants (including Ala603Ile) confirmed that mutagenesis abolishes both 5S-lipoxygenation and LTA4 synthase activity, with QM/MM modeling showing altered substrate alignment, completing the structural picture of ALOX5 specificity.\",\n      \"evidence\": \"Recombinant Sf9 expression; HPLC; stereospecifically deuterium-labeled substrates; in silico docking, MD, QM/MM\",\n      \"pmids\": [\"31664810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimentally determined crystal structure of mutant active site\", \"Dynamics of substrate entry into the pocket not characterized\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Systematic identification of ALOX5 promoter-binding proteins revealed G-quadruplex structures in the GC-rich promoter and identified novel transcriptional regulators (KLF13, KLF16, MAZ, ZBTB7A) and G-quadruplex interactors (BLM, DHX36), expanding the regulatory landscape beyond Sp1/Egr1.\",\n      \"evidence\": \"DNA pulldown coupled to label-free quantitative mass spectrometry; circular dichroism spectroscopy; antibody-based G-quadruplex detection\",\n      \"pmids\": [\"32096311\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional validation of individual novel regulators not performed\", \"Whether G-quadruplex structures regulate transcription in vivo is unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A PKCβ–ERK1/2–ALOX5–PTEN axis was defined as a mechanism of BCR-ABL-independent TKI resistance in CML, showing that ALOX5 inactivates PTEN downstream of ERK signaling to sustain resistance.\",\n      \"evidence\": \"shRNA knockdown; ERK inhibitors; PTEN activity assays; CML-PDX mouse model with PKCβ inhibitor\",\n      \"pmids\": [\"33561320\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism of PTEN inactivation by ALOX5 products not identified\", \"Single lab without independent replication\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ALOX5 was established as a caspase-9-parallel cell death executor: Erk1-dependent phosphorylation targets ALOX5 to the nuclear membrane where it mediates lipid peroxidation causing DNA damage and cell death; double knockout of caspase-9 and Alox5 causes T cell expansion in vivo, demonstrating non-redundant regulation of T cell homeostasis.\",\n      \"evidence\": \"Genome-wide siRNA screen; caspase-9/Alox5 double-KO mice; ROS/lipid peroxidation assays; subcellular imaging\",\n      \"pmids\": [\"36231015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of specific lipid peroxidation products at the nuclear membrane not determined\", \"Whether this pathway operates in non-T cell lineages unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ERK-dependent ALOX5 activation was shown to mediate ferroptosis in neurons downstream of lysyl oxidase, linking ALOX5 to seizure-induced hippocampal neuronal death.\",\n      \"evidence\": \"AAV-based LysOX overexpression; ERK inhibitor studies; lipid peroxidation assays; seizure mouse model\",\n      \"pmids\": [\"36176900\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ALOX5-mediated neuronal ferroptosis is ACSL4-dependent or independent not clarified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ALOX5 was linked to Huntington's disease pathogenesis: polyglutamine-expanded huntingtin stabilizes FLAP, enhancing ALOX5 activity and triggering ferroptosis selectively under HD-relevant stress; Alox5 knockout ameliorates HD pathology and extends lifespan in HD mice.\",\n      \"evidence\": \"RNAi genome screen; ALOX5–FLAP co-IP and stabilization assays; neuronal ferroptosis assays; Alox5 KO in HD mouse model\",\n      \"pmids\": [\"36921996\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which mutant huntingtin stabilizes FLAP not fully elucidated\", \"Whether ALOX5 inhibition benefits manifest HD not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Multiple studies established ALOX5-derived 5-HETE and LTB4 as drivers of immunosuppressive M2 macrophage polarization across cancer types, acting through JAK/STAT in pancreatic cancer, PI3K via BLT1/BLT2 in cholangiocarcinoma, and NRF2 nuclear translocation in glioma, while EGR1-dependent ALOX5 expression was shown to be required for ferroptosis sensitivity in bladder cancer.\",\n      \"evidence\": \"Lentiviral overexpression; zileuton and receptor-blocking studies; orthotopic and xenograft mouse models; CRISPR/Cas9 KO; ChIP for EGR1; oxylipin profiling\",\n      \"pmids\": [\"37348233\", \"38124204\", \"39142719\", \"38062004\", \"37080437\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the M2-promoting and ferroptosis-promoting roles of ALOX5 are context-exclusive or coexist in a single tumor is unresolved\", \"Relative contribution of LTB4 versus 5-HETE to immunosuppression not established in a unified system\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A complete LTB4–ORAI3–NLRP3 pyroptosis pathway was delineated in CD4+ T cells from RA patients, showing that ALOX5-derived LTB4 triggers Ca2+ influx through ORAI3, activating NLRP3 inflammasome-mediated pyroptosis, with in vivo validation in two rodent arthritis models.\",\n      \"evidence\": \"Patient T cell analysis; ALOX5 knockdown; LTB4 ELISA; Ca2+ flux assays; ORAI3 blocking; NLRP3 activation; two rodent RA models\",\n      \"pmids\": [\"38412254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway operates in other autoimmune T cell–driven diseases unknown\", \"Structural basis of LTB4–ORAI3 interaction not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"PARP-1 was identified as a post-translational stabilizer of ALOX5 through PARylation, linking DNA damage response signaling to leukotriene biosynthesis in tumor-associated neutrophils.\",\n      \"evidence\": \"Co-IP/mass spectrometry; PARylation assay; PARP-1 knockdown and inhibitor; murine tumor model\",\n      \"pmids\": [\"38172525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PARylation site(s) on ALOX5 not mapped\", \"Whether PARylation affects ALOX5 enzymatic activity or only stability not distinguished\", \"Not replicated independently\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: (1) how ALOX5 functions as a pro-tumorigenic factor in CML/PV while acting as a PRC2-repressed tumor suppressor in MLL-AML; (2) which specific lipid products mediate nuclear-membrane ferroptosis versus conventional leukotriene signaling; (3) the structural basis of FLAP stabilization by mutant huntingtin; and (4) whether ALOX5 promoter G-quadruplex structures regulate transcription in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Context-dependent oncogene vs. tumor suppressor function not mechanistically reconciled\", \"No crystal structure of ALOX5–FLAP complex\", \"In vivo relevance of G-quadruplex promoter regulation untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [3, 5, 9, 13]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [5, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [28, 29]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [28, 18]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [18, 28]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 5, 9, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 25, 21, 23, 27]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [18, 19, 20, 22, 24, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 16, 17, 21, 23, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 7, 11, 14, 15, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FLAP\",\n      \"PARP1\",\n      \"SP1\",\n      \"EGR1\",\n      \"KLF6\",\n      \"ORAI3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}